RayzeBio

7 Billion-Dollar Oncology M&As from Q1
BioSpace
Wed, 04/10/24 - 11:24 am
oncology
M&A
AbbVie
Immunogen
Bristol Myers Squibb
Mirati Therapeutics
RayzeBio
Novartis
MorphoSys
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
Gracell
BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotech went public
Fierce Biotech
Wed, 12/27/23 - 11:15 pm
Bristol Myers Squibb
RayzeBio
radiopharmaceuticals
M&A
Biopharma’s top 5 IPOs of 2023 (so far)
Pharma Voice
Thu, 11/30/23 - 10:01 am
biotech
IPOs
Acelyrin
Apogee Therapeutics
RayzeBio
Neumora Therapeutics
Mineralys Therapeutics
How biotech IPOs performed in the third quarter
BioPharma Dive
Tue, 10/3/23 - 10:28 am
biotech
IPOs
Adlai Nortye
RayzeBio
Neumora Therapeutics
Mira Pharmaceuticals
Turnstone Biologics
Apogee Therapeutics
Sagimet Biosciences
60 Degrees Pharma
5 Life Sciences IPOs in 2023—and the Future Forecast
BioSpace
Wed, 09/20/23 - 08:51 am
Neumora Therapeutics
RayzeBio
Adlai Nortye
Jyong Biotech
Metagenomi
RayzeBio, Neumora price some of biotech’s largest IPOs this year
BioPharma Dive
Thu, 09/14/23 - 11:02 pm
IPOs
RayzeBio
Neumora Therapeutics
With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success
Endpoints
Tue, 09/13/22 - 07:54 pm
RayzeBio
radiopharmaceuticals
After Big Pharma sparked interest in the US, Ablaze looks to bring radiopharmaceuticals overseas
Endpoints
Tue, 11/30/21 - 10:26 am
Ablaze Pharmaceuticals
funding
RayzeBio
China
radiopharmaceuticals
TRTs
Just shy of its 1-year anniversary, radiopharmaceuticals platform play RayzeBio bags another megaround
Endpoints
Tue, 06/15/21 - 10:43 am
RayzeBio
funding
radiopharmaceuticals
Barely two months after unveiling a new breed of radiopharmaceuticals, RayzeBio brings total haul to $150M
Endpoints
Tue, 12/8/20 - 10:52 am
RayzeBio
radiopharmaceuticals
Versant
venBio